Axsome Therapeutics Reports Q1 2026 Earnings

In its first-quarter earnings call on May 4, 2026, Axsome Therapeutics reported total revenue of $191 million from three marketed products, representing a year-over-year growth of 57%. The company highlighted strong performance driven by AUVELITY and SUNOSI. Additionally, the FDA approved AUVELITY for treating agitation associated with Alzheimer's disease.

By Motley Fool Transcribing, The Motley Fool May 4, 2026 45 min read · Yahoo Finance · May 4, 2026, 15:37 UTC

Tickers: $AXSM

Topics: FDA approval neurology pharmaceuticals R&D pipeline

Read the full article at Yahoo Finance

More World news

Fennec Pharmaceuticals Reports Record Q3 2026 Results with Significant EBITDA Growth Motley Fool · November 12, 2026, 16:11 UTC
Rockwell Medical Reports Q3 2026 Results and Announces Vantive Limited Acquisition Motley Fool · November 12, 2026, 16:11 UTC
BioHarvest Sciences Reports Q3 2026 Financial Results Amid Strategic Shift to Fragrance Development Motley Fool · November 12, 2026, 16:11 UTC
Xunlei Reports Q3 2026 Revenue Growth Amid Increased Operating Losses and Investment Adjustments Motley Fool · November 12, 2026, 16:11 UTC
Sandisk Shares Decline Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 16:14 UTC
Donald Trump Suggests Tim Cook as Potential Successor for Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 16:09 UTC
Yankees President Randy Levine Advocates for Protect College Sports Act and Addresses MLB Labor Uncertainty CNBC · November 12, 2026, 15:34 UTC
Donald Trump Suggests Apple Chairman Tim Cook as Potential Successor to Nvidia CEO Jensen Huang TechCrunch · November 12, 2026, 16:12 UTC
Bybit Announces Title Partnership for Inaugural Stockholm Open ATP 250 Tournament PR Newswire · November 12, 2026, 16:11 UTC
SES AI Reports Q3 2026 Revenue Growth Amid Strategic Shift Toward Drone Battery Market Motley Fool · November 12, 2026, 16:10 UTC